Neurocrine buys Soleno Therapeutics for $2.9 billion amid biotech shift
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion in an all-cash deal on April 6, 2026. The acquisition focuses on Soleno's VYKAT XR, a treatment for rare diseases. This move comes as the biotech industry shifts its dealmaking focus.
Acquisition Details
Neurocrine Biosciences announced its acquisition of Soleno Therapeutics for $2.9 billion in an all-cash transaction. The deal centers on Soleno's VYKAT XR, a drug targeting rare diseases. This acquisition marks a significant investment in the rare disease sector, reflecting a broader industry trend. Soleno's board has unanimously approved the transaction, which is expected to close by the end of the year.
Biotech Industry Trends
The acquisition highlights a shift in the biotech industry towards rare disease treatments. Neurocrine's move follows similar strategies by other major pharmaceutical companies. The focus on rare diseases is driven by high unmet medical needs and potential for premium pricing. Analysts note that such deals are becoming more common as companies seek to diversify their portfolios.
What's Next
The deal awaits regulatory approval, which is anticipated in the coming months. It remains unclear how this acquisition will impact Neurocrine's market position.
1 source
Neurocrine buys Soleno Therapeutics for $2.9 billion amid biotech shift
